Comprehensive Overview

The Group is a clinical biopharmaceutical company that focuses on developing innovative and differentiated small-molecule tumor therapies. In the current stage, the group mainly develops core candidate products for the treatment of hepatocellular carcinoma (HCC), urothelial carcinoma (UC) and gastric cancer (GC). Since its establishment in 2016, the Group has developed a pipeline of 14 candidate drug compositions focused on oncology, including five candidate drugs at the clinical stage. Precision cancer treatment accounted for the largest share of the global oncology drug market in 2020, accounting for about 60.4% of the market in terms of revenue. It is estimated that by 2030, precision tumor treatment and tumor immunotherapy will together account for about 90% of the global tumor market.

Risk Factors

The tumor market is fiercely competitive. In addition to existing products, it also faces competition for products that are currently under development. Discovering new drug candidates and formulations or seeking research projects to develop candidate drugs for other suitable conditions requires significant technical, financial and human resources. Clinical trials are expensive, they can take years to complete, and the results themselves are full of uncertainty. The number of suppliers in the Group's track record period is limited, and the loss of one or more major suppliers may cause the Group to disrupt operations.